• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    5/22/23 1:20:39 PM ET
    $ABSI
    $ADSE
    $AKBA
    $AULT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Industrial Specialties
    Consumer Discretionary
    Get the next $ABSI alert in real time by email

    Gainers

    • Greenhill & Co., Inc. (NYSE:GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
    • AVROBIO, Inc. (NASDAQ:AVRO) gained 93.5% to $1.50 after the company announced it would sell its gene therapy program to Novartis for $87.5 million.
    • Microbot Medical Inc. (NASDAQ:MBOT) rose 66% to $2.0450 after the company announced it achieved a 100% success rate for the LIBERTY system in an extensive pre-clinical animal study performed by leading European physicians.
    • Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares gained 39.7% to $12.45 after the company announced results of its phase 2 study to treat liver function.
    • VectivBio Holding AG (NASDAQ:VECT) climbed 38.5% to $16.20 after Ironwood Pharmaceuticals announced it would acquire the company for $17 per share.
    • Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) shares climbed 33.5% to $4.9375. Tang Capital Partners, Concentra sent acquisition proposal to Atea Pharmaceuticals with terms to acquire all of its outstanding common stock.
    • Appreciate Holdings, Inc. (NASDAQ:SFR) gained 30% to $0.3551. Appreciate announced receipt of notice from Nasdaq regarding late filing of its form 10-Q and 10-K.
    • D-Wave Quantum Inc. (NYSE:QBTS) surged 25.5% to $0.6080. Benchmark reiterated D-Wave Quantum with a Buy and maintained a $2 price target.
    • CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) shares climbed 24.3% to $1.9850 after gaining around 18% on Friday. CNS Pharmaceuticals posted a wider first-quarter loss.
    • SeqLL Inc. (NASDAQ:SQL) shares climbed 23.9% to $0.4149 after dropping 14% on Friday. SeqLL recently posted a wider first-quarter loss.
    • Cricut, Inc. (NASDAQ:CRCT) gained 22.2% to $8.78. Cricut declared a $234 million special cash dividend of $1/share to holders of the company’s Class A and Class B common stock.
    • Yunji Inc. (NASDAQ:YJ) gained 19.8% to $0.22.
    • Histogen Inc. (NASDAQ:HSTO) rose 18.7% to $1.00.
    • Absci Corporation (NASDAQ:ABSI) jumped 18.7% to $1.65.
    • ADS-TEC Energy PLC (NASDAQ:ADSE) rose 18.6% to $7.13.
    • Akebia Therapeutics, Inc. (NASDAQ:AKBA) climbed 18.1% to $1.37 after the company announced UK MHRA approval of Vafseo for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
    • Peraso Inc. (NASDAQ:PRSO) gained 17.3% to $0.3050. Benchmark maintained Peraso with a Buy and lowered the price target from $2.5 to $1.5.
    • Outlook Therapeutics, Inc. (NASDAQ:OTLK) rose 17.2% to $1.57.
    • Rackspace Technology, Inc. (NASDAQ:RXT) jumped 16.6% to $1.3185.
    • Netcapital Inc. (NASDAQ:NCPL) shares gained 16.1% to $2.29 after gaining over 6% on Friday.
    • Upstart Holdings, Inc. (NASDAQ:UPST) jumped 14.6% to $26.41.
    • Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) surged 14.5% to $7.36.
    • CI&T Inc (NASDAQ:CINT) gained 14.2% to $4.0750. CI&T recently reported Q1 financial results.
    • ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) rose 13.1% to $0.4821 after the company reported changes to ZyVersa’s board of directors.
    • IonQ, Inc. (NASDAQ:IONQ) gained 13% to $10.04.
    • Nanobiotix S.A. (NASDAQ:NBTX) gained 12.5% to $5.25. NANOBIOTIX recently issued an update on operational progress and reported financial results for the for the first quarter.
    • Kodiak Sciences Inc. (NASDAQ:KOD) climbed 12.2% to $6.63. Kodiak Sciences recently reported a year-over-year increase in first-quarter EPS.
    • Celularity Inc. (NASDAQ:CELU) shares climbed 9.6% to $0.7124. Celularity highlighted presentation of Phase 1 data on MLASC therapy in patients with Crohn's Disease.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) shares rose 8.5% to $1.7812 after the company announced NXC-201 clinical results showed 100% overall response rate in DARZALEX-relapsed or refractory AL amyloidosis with zero ICANs in the ongoing NEXICART-1 Phase 1b/2a trial.
    • NIO Inc. (NYSE:NIO) gained 7.7% to $8.69 after the Chinese government announced interest rates would remain unchanged.

    Losers

    • Rain Oncology Inc. (NASDAQ:RAIN) shares dipped 87.3% to $1.2700 after the company’s Phase 3 MANTRA trial of milademetan in dedifferentiated liposarcoma, did not meet its primary endpoint of progression-free survival, compared to the standard of care, trabectedin.
    • Mallinckrodt plc (NYSE:MNK) fell 45.1% to $3.46.
    • Monogram Orthopaedics, Inc. (NASDAQ:MGRM) dropped 36% to $8.65.
    • Volcon, Inc. (NASDAQ:VLCN) fell 34.5% to $0.7125 as the company reported $9 million in securities offerings and pricing of previously announced public offering.
    • Bright Health Group, Inc. (NYSE:BHG) dropped 27% to $12.18.
    • Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) fell 24.3% to $10.27. FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceuticals’ Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH) patients with stage 2 or 3 fibrosis.
    • Daxor Corporation (NASDAQ:DXR) shares dropped 23.1% to $9.61 after the company reported pricing of $4.0 million underwritten public offering.
    • SunCar Technology Group Inc. (NASDAQ:SDA) fell 22.5% to $6.03 amid continued volatility following the recent completion of the company's combination with Goldenbridge Acquisition to become a publicly-traded company.
    • Enveric Biosciences, Inc. (NASDAQ:ENVB) dipped 21.2% to $2.79. Enveric Biosciences announced manuscript detailing the development of novel psilocin prodrugs for the treatment of anxiety and other mental health disorders.
    • Interactive Strength Inc. (NASDAQ:TRNR) fell 20.7% to $5.61.
    • Sigilon Therapeutics, Inc. (NASDAQ:SGTX) fell 18.3% to $0.51 after the company announced a 1-for-13 reverse stock split.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) dropped 17.5% to $0.2303.
    • WaveDancer, Inc. (NASDAQ:WAVD) dipped 16% to $0.3359.
    • Ault Alliance, Inc. (NYSE:AULT) dropped 15.3% to $12.45. Ault Alliance and BitNile Metaverse launched social gaming on the platform with the launch of Online Roulette.
    • ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) dipped 13.9% to $15.07 after the company reported a year-over-year decrease in first-quarter EPS results and worse-than-expected sales results.
    • Baudax Bio, Inc. (NASDAQ:BXRX) fell 13.2% to $0.55. Baudax Bio recently posted a first-quarter loss of $3.19 per share.
    • Biocept, Inc. (NASDAQ:BIOC) shares dropped 10.1% to $5.98. Biocept recently announced a 1-for-30 reverse stock split..
    • Nutex Health Inc. (NASDAQ:NUTX) fell 8.7% to $0.5081.
    • Flora Growth Corp. (NASDAQ:FLGC) fell 8% to $0.2392 after surging 8% on Friday. Flora Growth recently posted a narrower-than-expected quarterly loss.
    • The Vita Coco Company, Inc. (NASDAQ:COCO) dropped 7.6% to $22.57 after the company reported a secondary offering of 4.5 million shares of common stock by selling stockholder.
    • Icahn Enterprises L.P. (NASDAQ:IEP) fell 5.8% to $30.33.
    • Micron Technology, Inc. (NASDAQ:MU) shares dropped 4.1% to $65.43 after China banned some of its product sales after a seven-week investigation into Micron.

    Now Read This: Ethereum Trades Above $1,800; TRON Becomes Top Gainer

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI
    $ADSE
    $AKBA
    $AULT

    CompanyDatePrice TargetRatingAnalyst
    Micron Technology Inc.
    $MU
    3/19/2026Buy → Hold
    Summit Insights
    Micron Technology Inc.
    $MU
    3/19/2026$450.00 → $500.00Buy
    Needham
    Upstart Holdings Inc.
    $UPST
    3/16/2026$43.00Neutral → Buy
    BTIG Research
    NIO Inc.
    $NIO
    3/13/2026$6.80Hold → Buy
    HSBC Securities
    NIO Inc.
    $NIO
    3/11/2026$6.60Neutral → Buy
    Nomura
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    Upstart Holdings Inc.
    $UPST
    2/17/2026$30.00Sell → Neutral
    Compass Point
    Micron Technology Inc.
    $MU
    2/17/2026$380.00 → $450.00Buy
    Needham
    More analyst ratings

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Innovation Officer Busch Andreas bought $229,000 worth of shares (100,000 units at $2.29), increasing direct ownership by 31% to 421,446 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/16/26 4:17:22 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    CEO and President Butler John P. bought $86,588 worth of shares (69,270 units at $1.25), increasing direct ownership by 2% to 3,367,064 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    3/5/26 6:55:46 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sinha Dharmendra Kumar

    4 - Rackspace Technology, Inc. (0001810019) (Issuer)

    3/18/26 8:38:17 PM ET
    $RXT
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Marino Mark A.

    4 - Rackspace Technology, Inc. (0001810019) (Issuer)

    3/18/26 8:38:12 PM ET
    $RXT
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Taylor Ben R

    4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

    3/18/26 5:52:36 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABSI
    $ADSE
    $AKBA
    $AULT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    2/25/22 4:36:46 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    5/27/21 5:23:24 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ADSE
    $AKBA
    $AULT
    SEC Filings

    View All

    SEC Form 6-K filed by ZIM Integrated Shipping Services Ltd.

    6-K - ZIM Integrated Shipping Services Ltd. (0001654126) (Filer)

    3/19/26 7:29:01 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    SEC Form 144 filed by Rackspace Technology Inc.

    144 - Rackspace Technology, Inc. (0001810019) (Subject)

    3/18/26 8:18:29 PM ET
    $RXT
    Computer Software: Programming Data Processing
    Technology

    Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

    8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    3/18/26 4:15:09 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZIM Updates on Withholding Tax Procedures on March 2026 Cash Dividend

    HAIFA, Israel, March 19, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a global container liner shipping company, hereby updates that in connection with the dividend distribution expected to take place on March 26, 2026, as previously announced by the Company on March 9, 2026 (the "Dividend"), the previously obtained tax ruling from the Israeli Tax Authority ("ITA") on tax withholding procedures relating to the payment of the Dividend to the Company's shareholders (the "Ruling"), as extended, shall apply.   As a result of the Ruling, certain shareholders of the Company ("Shareholders") may be eligible to a reduced Israeli withholding tax rate

    3/19/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    Micron Technology, Inc. Reports Results for the Second Quarter of Fiscal 2026

    BOISE, Idaho, March 18, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (NASDAQ:MU) today announced results for its second quarter of fiscal 2026, which ended February 26, 2026. Fiscal Q2 2026 highlights Revenue of $23.86 billion versus $13.64 billion for the prior quarter and $8.05 billion for the same period last yearGAAP net income of $13.79 billion, or $12.07 per diluted shareNon-GAAP net income of $14.02 billion, or $12.20 per diluted shareOperating cash flow of $11.90 billion versus $8.41 billion for the prior quarter and $3.94 billion for the same period last year "Micron set new records across revenue, gross margin, EPS, and free cash flow in fiscal Q2, driven by a strong dem

    3/18/26 4:01:00 PM ET
    $MU
    Semiconductors
    Technology

    Enveric Biosciences Announces Registration of Five Trademarks

    Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company's trademarks, including its house marks, Enveric and Enveric Biosciences. "The registration of a Company's house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property

    3/18/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Micron downgraded by Summit Insights

    Summit Insights downgraded Micron from Buy to Hold

    3/19/26 8:25:02 AM ET
    $MU
    Semiconductors
    Technology

    Needham reiterated coverage on Micron with a new price target

    Needham reiterated coverage of Micron with a rating of Buy and set a new price target of $500.00 from $450.00 previously

    3/19/26 7:49:58 AM ET
    $MU
    Semiconductors
    Technology

    Upstart upgraded by BTIG Research with a new price target

    BTIG Research upgraded Upstart from Neutral to Buy and set a new price target of $43.00

    3/16/26 8:34:06 AM ET
    $UPST
    Finance: Consumer Services
    Finance

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Leadership Updates

    Live Leadership Updates

    View All

    ZIM Updates on Withholding Tax Procedures on March 2026 Cash Dividend

    HAIFA, Israel, March 19, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a global container liner shipping company, hereby updates that in connection with the dividend distribution expected to take place on March 26, 2026, as previously announced by the Company on March 9, 2026 (the "Dividend"), the previously obtained tax ruling from the Israeli Tax Authority ("ITA") on tax withholding procedures relating to the payment of the Dividend to the Company's shareholders (the "Ruling"), as extended, shall apply.   As a result of the Ruling, certain shareholders of the Company ("Shareholders") may be eligible to a reduced Israeli withholding tax rate

    3/19/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Financials

    Live finance-specific insights

    View All

    Micron Technology, Inc. Reports Results for the Second Quarter of Fiscal 2026

    BOISE, Idaho, March 18, 2026 (GLOBE NEWSWIRE) -- Micron Technology, Inc. (NASDAQ:MU) today announced results for its second quarter of fiscal 2026, which ended February 26, 2026. Fiscal Q2 2026 highlights Revenue of $23.86 billion versus $13.64 billion for the prior quarter and $8.05 billion for the same period last yearGAAP net income of $13.79 billion, or $12.07 per diluted shareNon-GAAP net income of $14.02 billion, or $12.20 per diluted shareOperating cash flow of $11.90 billion versus $8.41 billion for the prior quarter and $3.94 billion for the same period last year "Micron set new records across revenue, gross margin, EPS, and free cash flow in fiscal Q2, driven by a strong dem

    3/18/26 4:01:00 PM ET
    $MU
    Semiconductors
    Technology

    NIO Inc. Reports Unaudited Fourth Quarter and Full Year 2025 Financial Results

    Quarterly Adjusted Profit From Operations (non-GAAP) Reached RMB1,251.3 Million (US$178.9 Million)i Quarterly Total Revenues Reached RMB34,650.2 Million (US$4,954.9 Million)iQuarterly Vehicle Deliveries Were 124,807 Units Full Year Total Revenues Reached RMB87,487.5 Million (US$12,510.5 Million) Full Year Vehicle Deliveries Were 326,028 Units SHANGHAI, China, March 10, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025. Operating Highlights for the Fourth Quarter

    3/10/26 6:30:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    ZIM Reports Financial Results for the Fourth Quarter and the Full Year of 2025

    Reported Full Year Revenues of $6.90 Billion, Net Income of $481 Million1, Adjusted EBITDA2 of $2.17 Billion and Adjusted EBIT2 of $885 Million3Generated Full Year Adjusted EBITDA and Adjusted EBIT Margins2 of 31% and 13%, Respectively Declared Q4 2025 Dividend of Approximately $106 Million, or $0.88 per Share, Representing, Together with Previous Dividends Distributed on Account of 2025 Results, Approximately 50% of the Full Year 2025 Net Income Dividends to Total Approximately $5.8 Billion Over Last Five Years—More Than 25 Times the Amount Raised at IPO in January 2021HAIFA, Israel, March 9, 2026 /PRNewswire/ -- ZIM Integrated Shipping Services Ltd. (NYSE:ZIM) ("ZIM" or the "Company"), a g

    3/9/26 7:00:00 AM ET
    $ZIM
    Marine Transportation
    Consumer Discretionary

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    11/15/24 10:34:54 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ADSE
    $AKBA
    $AULT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care